Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer
Madeleine King(The University of Sydney), Bruce K. Armstrong(University of New Mexico), Phillip D. Stricker(Prostate Cancer Foundation of Australia), Elizabeth Savage(University of Technology Sydney), Ishrat Hossain(University of Technology Sydney), Jeanette Ward(Target (United States)), Deborah J. Street(University of Technology Sydney), Martin Berry(Macquarie University), Martin R. Stockler, Paul Cozzi(St George Hospital), Stephanie L. Fowler(University of Oxford), Rosalie Viney(University of Technology Sydney), David P. Smith(The University of Sydney)
Cited by 49
Related Papers
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
|Journal of Clinical Oncology|1996|1.6k
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium
|The Lancet Oncology|2005|378
A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology
|Nature Neuroscience|2018|274
Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls
|International Journal of Epidemiology|2009|252